Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
15
OM Quote, Financials, Valuation and Earnings
Last price:
$3.30
Seasonality move
:
-28.25%
Day range:
$3.26 - $3.39
52-week range:
$3.26 - $25.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.65x
P/B ratio:
0.42x
Volume:
283.1K
Avg. volume:
597.4K
1-year change:
-80.59%
Market cap:
$58.5M
Revenue:
$113.7M
EPS (TTM):
-$13.00
Analysts' Opinion
-
Consensus RatingOutset Medical, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.25, Outset Medical, Inc. has an estimated upside of 302.74% from its current price of $3.29.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $3.29.
Fair Value
-
According to the consensus of 4 analysts, Outset Medical, Inc. has 302.74% upside to fair value with a price target of $13.25 per share.
OM vs. S&P 500
-
Over the past 5 trading days, Outset Medical, Inc. has underperformed the S&P 500 by -13.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Outset Medical, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Outset Medical, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Outset Medical, Inc. reported revenues of $29.4M.
Earnings Growth
-
Outset Medical, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Outset Medical, Inc. reported earnings per share of -$1.00.
Enterprise value:
-17.7M
EV / Invested capital:
-0.07x
Price / LTM sales:
0.65x
EV / EBIT:
--
EV / Revenue:
-0.15x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.33x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$45.3M
Return On Assets:
-30.57%
Net Income Margin (TTM):
-73.13%
Return On Equity:
-81.05%
Return On Invested Capital:
-35.38%
Operating Margin:
-53.73%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $131.9M | $114.7M | $120.1M | $28.7M | $29.4M | |
| Gross Profit | $26.6M | $35.5M | $45.3M | $9.8M | $11.6M | |
| Operating Income | -$172.2M | -$128.9M | -$69.5M | -$23.8M | -$15.8M | |
| EBITDA | -$165.4M | -$123.1M | -$64.7M | -$22.4M | -$14.8M | |
| Diluted EPS | -$3.58 | -$2.77 | -$13.00 | -$0.55 | -$1.00 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $433.3M | $310M | $283.8M | $275.3M | $265.4M | |
| Total Assets | $488.8M | $365.7M | $307.6M | $292.9M | $277.3M | |
| Current Liabilities | $41.4M | $49.6M | $53M | $42.4M | $37.4M | |
| Total Liabilities | $79.1M | $86.6M | $155.5M | $245.1M | $134.9M | |
| Total Equity | $409.8M | $279.1M | $152.1M | $47.8M | $142.4M | |
| Total Debt | $36.9M | $35.8M | $101.7M | $200.3M | $96.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$141.3M | -$124.3M | -$53.3M | -$20.6M | -$6.3M | |
| Cash From Investing | $7.9M | $19.2M | $1.9M | $15.9M | $3M | |
| Cash From Financing | $75.9M | $102M | $54.6M | $121K | $231K | |
| Free Cash Flow | -$145.8M | -$126.2M | -$53.9M | -$21M | -$6.5M | |
OM
Sector
Market Cap
$58.5M
$28M
Price % of 52-Week High
12.98%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-29.87%
-1.54%
1-Year Price Total Return
-80.59%
-17.48%
Beta (5-Year)
2.030
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.66
200-day SMA
Sell
Level
$13.21
Bollinger Bands (100)
Sell
Level
6.44 - 15.34
Chaikin Money Flow
Sell
Level
-19.2M
20-day SMA
Sell
Level
$4.08
Relative Strength Index (RSI14)
Sell
Level
21.10
ADX Line
Sell
Level
46.09
Williams %R
Buy
Level
-98.2456
50-day SMA
Sell
Level
$7.86
MACD (12, 26)
Sell
Level
-1.07
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Sell
Level
-22.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.3419)
Sell
CA Score
(Annual)
Level (-3.0928)
Buy
Beneish M-Score
(Annual)
Level (-32.0801)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.6315)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.
Stock Forecast FAQ
In the current month, OM has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The OM average analyst price target in the past 3 months is $13.25.
-
Where Will Outset Medical, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Outset Medical, Inc. share price will rise to $13.25 per share over the next 12 months.
-
What Do Analysts Say About Outset Medical, Inc.?
Analysts are divided on their view about Outset Medical, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Outset Medical, Inc. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Outset Medical, Inc.'s Price Target?
The price target for Outset Medical, Inc. over the next 1-year time period is forecast to be $13.25 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is OM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Outset Medical, Inc. is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OM?
You can purchase shares of Outset Medical, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Outset Medical, Inc. shares.
-
What Is The Outset Medical, Inc. Share Price Today?
Outset Medical, Inc. was last trading at $3.30 per share. This represents the most recent stock quote for Outset Medical, Inc.. Yesterday, Outset Medical, Inc. closed at $3.29 per share.
-
How To Buy Outset Medical, Inc. Stock Online?
In order to purchase Outset Medical, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get OM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
OM
Sector
P/E ratio
--
23.89x
PEG ratio
0.00x
-0.01x
P/B ratio
0.42x
1.82x
Price / LTM sales
0.65x
1.60x
Growth Metrics
OM
Sector
Revenue growth
2.67%
4.62%
Earnings growth
-81.29%
10.88%
Revenue (5-year growth)
49.79%
6.5%
Earnings forecast
-$0.70
-$0.21
Profitability
OM
Sector
Profitability FY 2024
$39.1M
$3.5M
Return on invested capital
-35.38%
-31.77%
Return on assets
-30.57%
-27.96%
Return on equity
-81.05%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Feb
18
Estimated Next Earnings Date
Feb
9
Balance Sheet
OM
Sector
Total cash
$178.6M
$26.3M
Short term investments
$34.7M
$25.7M
Total assets
$275.8M
$78M
Long term debt
$96.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
